DailyIQ
|
Sector:HealthcareAll sectors
Last updated 16 minutes ago

THC·THC

$.
-. (-.%)
After Hours
High
$235.50
Open
$231.16
Market Cap
20.31B
52W High
$235.77
Low
$227.47
P. Close
$181.06
P/E
15.00
52W Low
$109.82
Fwd P/E
-
Mean Target
$254.95
Technical Score (1D)
77
BUY
News Sentiment
70
BULLISH
Recent analyst upgrades signal a positive outlook for Tenet Healthcare (THC). UBS raised its price target to $288 and maintained a Buy rating, while Deutsche Bank increased its target to $260, also with a Buy rating. RBC also increased its price target to $277 and maintained an Outperform rating. These adjustments reflect growing confidence in the company's performance. THC's Q4 results further support this positive sentiment. The company exceeded revenue expectations, with ambulatory surgical centers and expense management driving outperformance. Management cited ambulatory growth and expense control as key drivers. The company's 2025 net operating revenues reached $21.3 billion, with consolidated Adjusted EBITDA of $4.57 billion, a 14% increase from the prior year. The strong performance in both the ambulatory and hospital segments, along with positive 2026 guidance, suggests continued momentum. However, it's worth noting that while the average analyst rating remains Buy, the price targets vary, so investors should monitor these developments closely.
Earnings Summary
Tenet Healthcare Corporation, operating in the Healthcare sector within the Medical Care Facilities industry, is a diversified healthcare services company in the United States. The company operates through Hospital Operations and Services, and Ambulatory Care segments, providing a range of acute, outpatient, and tertiary care services. Recent news indicates a positive outlook, with analyst upgrades and strong Q4 2025 earnings. In Q4 2025, Tenet Healthcare reported revenue of $5.53 billion and an adjusted EPS of $4.70, exceeding analyst expectations, a significant increase from the previous quarter. The company's Q4 2024 results showed an EPS of $3.44 with revenue at $5.07 billion. The company's Q1 2026 EPS and revenue are not available. The company beat estimates in both quarters where data is available. The company's 2025 net operating revenues reached $21.3 billion, with a 14% increase in consolidated adjusted EBITDA to $4.57 billion. YoY growth trajectory is positive, with strong performance in both hospital and ambulatory surgery divisions. The company has a history of exceeding revenue expectations. The ambulatory care segment saw a significant revenue increase, and the hospital segment also showed robust growth. Management attributes margin improvement to standardized labor and supply practices, and the company is actively pursuing acquisitions in the ASC space. Recent news highlights strong Q4 2025 earnings, driven by strong results in both hospital and ambulatory surgery divisions, leading to optimistic guidance for 2026. Analysts are projecting a 7.8% year-over-year revenue increase to $5.47 billion. The company's strategic shift toward high-acuity services and disciplined cost control led to margin expansion. Looking ahead, investors should watch for the Q1 2026 earnings report, particularly the EPS figures and any revisions to full-year guidance. Key will be the continued growth in the ambulatory care segment and the hospital segment's performance, as well as management's commentary on the earnings call for insights into future performance.

EPS

EstBeatMiss
$2.55$3.16$3.77$4.37$4.98Q4'24Q4'25Q1'26
QtrEstActual+/−
Q1'26$4.20 - -
Q4'25$4.09$4.70+14.8%
Q4'24$2.83$3.44+21.5%

Revenue

EstBeatMiss
$5.0B$5.2B$5.3B$5.4B$5.6BQ4'24Q4'25Q1'26
QtrEstActual+/−
Q1'26$5.4B - -
Q4'25$5.5B$5.5B+0.0%
Q4'24 - $5.1B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

THC Stock Snapshot

THC is currently trading at $231.10, giving THC a market cap of 20.31B and a P/E ratio of 15.0. Today's range spans $227.47–$235.50, with shares opening at $231.16 and moving up $50.04 (27.6%) from the prior close. DailyIQ's technical score sits at 77/100 (BUY) with a news sentiment reading of 70/100.

Over the past year THC has traded between $109.82 and $235.77 - the current price is +110.4% off the 52-week low and -2.0% from the high. 30 analysts cover the stock with a Buy consensus and a mean 12-month target of $254.95 (range $213.00–$288.00), implying upside of +10.3%.

THC (THC) is a large-cap in Healthcare with 20.31B in market cap, and the current setup is one of the cleaner bullish reads in the space. Technical score: 77/100 (BUY). Sentiment: bullish at 70/100. Price: $231.10 (near 52-week highs). The current P/E ratio stands at 15.0. The 52-week range of $109.82–$235.77 provides structural context - and the current technical/sentiment alignment is the type of setup that attracts both momentum and growth-oriented capital.

The combination of a BUY signal (77/100) and bullish news sentiment (70/100) puts THC on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 20.31B in Healthcare market cap without immediately moving the stock. At $231.10 (near 52-week highs in the $109.82–$235.77 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.